Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally and remains a major public health ...

Overview of Therapeutic Drug Monitoring MarketThe Global Therapeutic Drug Monitoring Market is valued at USD 2.5 Billion in ...

A common asthma inhaler has been recalled in the UK due to a labelling error that could mislead patients about their dosage.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

PEF failed to consistently reflect FEV1 improvements after bronchodilation, indicating that handheld spirometry may better ...

Kenvue, makers of Benadryl, introduces 'Cough Clinics' in partnership with the Association of Physicians of India. This initiative aims to establish ten Centers of Excellence across India. These ...

Kenvue and API launch India's first Cough Clinics to improve cough diagnosis and treatment. The initiative aims to address ...

Jeremy Derozin is the fifth trainer from AQHA's Top 10 earnings list in 2024 to be sidelined for a positive test of the non-FDA approved bronchodilator ...

Inhaled steroids aren’t the go-to treatment for COPD, so your doctor will likely prescribe a bronchodilator, too. This is medicine in an inhaler that relaxes your airway muscles to help you ...

The new recommendations specifically warn against anyone with asthma using a short-acting bronchodilator such as salbutamol by itself, due to the increased health risks mentioned above.

The odds for bronchodilator responsiveness significantly fell among patients who underwent spirometry testing in the afternoon vs. morning, according to findings published in Thorax.Additionally ...

HealthDay News — Patients are more likely to have positive bronchodilator responsiveness in the morning and in winter months, according to a study published online March 11 in Thorax.